H uman abdominal aortic aneurysm (AAA) is defined as a pathological dilatation that exceeds the normal diameter by 50% or that has an antero-posterior diameter of >30 mm. AAAs are a significant cause of morbidity and mortality in the United States and worldwide. The average incidence in Western civilizations is 0.4% to 0.67%. 1 Although mortality numbers are slowly decreasing because of better endovascular and open surgical repair techniques as well as better risk factor management, 2 AAAs still accounted for up to 10 000 deaths per year in the United States in 2014 or ≈3.1 deaths per 100 000 people. 3 Infiltration of monocytes/macrophages, polymorphonuclear leukocytes, and T and B lymphocytes mark the early phases of aneurysm development. 4 With further progression, a variety of cytokines, leukotrienes, and immunoglobulins attract additional inflammatory cells and establish a local vascular inflammatory response. Matrix degeneration with disruption of local collagen and elastin follows, accompanied by smooth muscle cell apoptosis in the aortic media, and ultimately leading to AAA expansion and rupture. 5, 6 With vascular inflammation being one of the major initial hallmarks of AAA formation, mechanisms that dampen the immune response might be leveraged to prevent progressive tissue damage. IL-10 (interleukin-10) is a well-described antiinflammatory cytokine, with a crucial role in suppression of inflammatory processes in diseases, such as environmental allergy, asthma, or inflammatory bowel disease. There is evidence that the immune-regulatory capacities of IL-10 might also be crucial in aneurysm development, as the IL-10-1082 A polymorphism (associated with lower IL-10 production 7 ) is more common in patients with AAA, 8 and patients with this polymorphism are at an increased risk of developing AAA. 9 IL-10 plasma concentrations in patients with AAA are significantly decreased compared with matched patients with coronary artery disease. 10 Also, IL-10-knockout mice show increased susceptibility to Ang II (angiotensin II)-induced aortic aneurysm and aortic rupture. 11 To our knowledge, no studies have to-date been conducted utilizing transgenic IL-10 animals.
IL-10 treatment has already been successfully performed in inflammatory bowel disease and glomerulosclerosis in rodents. However, recent studies have encountered major pitfalls. Intravenous or intraperitoneal injections of recombinant IL-10 need to be performed close to the time point of disease induction, or be repeated daily, because of IL-10's short plasma half-life. [12] [13] [14] In humans, outcomes in the treatment of inflammatory bowel disease did not demonstrate efficacy. 15 Although disease-specific reasons for these limited results may exist, 1 major drawback is the lack of sufficient IL-10 bioavailability at the tissue of interest. 16 To increase IL-10 bioavailability and to overcome IL-10 delivery issues, here we applied a nonviral minicircle transfection approach to the Ang II infusion-ApoE −/− AAA model. Minicircles are episomal DNA vectors lacking a bacterial plasmid backbone. Because of their small size compared with standard plasmids, they display higher transfection efficiency and survival rate of the target cells. In addition, minicircle constructs sustain a higher expression rate of their harboring transgenes over a longer period of time. This, combined with their low immunogenicity, makes them intriguing vectors for gene therapy.
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Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Mouse Model
B6.129P2-Apoetm1Unc/J male mice (ApoE −/− ) were transfected via intravenous injection of 25 µg minicircle into the retro-orbital venous plexus at a concentration of 25 µg/100 µL containing either a transgenic transcript for murine IL-10 or GFP (green fluorescent protein; control). Minicircle GFP was chosen as a control vector against minicircle IL-10 to adjust for the effects of actual translation of proteins from minicircle DNA to protein in transfected cells. Based on this approach, the experiment was performed as shown in Figure I in the online-only Data Supplement, showing that minicircle GFP did not alter aneurysm formation unexpectedly and randomly compared with Ang II+PBS treatment alone.
Seven days after transfection, aortic aneurysm formation was induced using continuous subcutaneous Ang II infusion. Osmotic pumps (model 2004, Alzet) containing either Ang II (1 μg/kg per minute; Sigma-Aldrich) or saline were implanted in ApoE −/− male mice (C57BL/6J background) as previously described. 20 Pump implantation occurred at 3 to 6 months of age (mean age, 168±7.6 days, total n=78), mice were age-matched before starting the experiment.
Suprarenal aortic diameter was followed via ultrasound measurements on a VisualSonics Vevo2100 for 28 days as previously described [21] [22] [23] and validated. 24 Diameter was assessed using the leading edge-to-leading edge method. 25 Lesions were classified as dissecting AAA if intramural hematoma was visible by ultrasound, by histology or at necropsy.
Bioluminescence imaging was performed with the Xenogen In Vivo Imaging System on days 1, 3, 9, and 15 after transfection. D-Luciferin (Promega) was administered intraperitoneally at a dose of 375 mg/kg of body weight.
Murine plasma was collected with a standardized method via mandibular vein and centrifuged at 15 minutes at 3000 rpm at 4°C. ELISA for IL-10 was performed according to the manufacturer's instructions (Quantikine ELISA Mouse IL-10 Immunoassay).
Construction and Amplification of Minicircle-IL-10 Plasmids
For minicircle amplification, a single colony Escherichia coli was grown at 37°C overnight and subsequently spun down. The pellet was redissolved with broth (pH 7.0) containing 1% L-(+)-arabinose and incubated at 30°C for 2 hours. Minicircle constructs were isolated from the culture using plasmid purification kits (Qiagen, Venlo, The Netherlands). Primers (cactagtcgcgcccggggag/gacccatgggggcccgcc) were used to polymerase chain reaction (PCR) minicircle DNA with attB/attP elements and obtain DNA fragment A. The cytomegalovirus promoter, multiple cloning site, and poly A elements were PCR-amplified from pcDNA3.1/zeo(+) (Invitrogen) with primers aattgcatgaagaatctgct/ctggttctttccgcctcaga to obtain DNA fragment B. Ligation of DNA fragment A and DNA fragment B resulted in vector C. The IL-10 coding sequence was synthesized and subcloned into the KpnI/XhoI site of vector C, resulting in pMC-IL10. For detailed methods, please see Huang et al 18 and Figure V in the online-only Data Supplement.
Similar minicircles bearing transcripts for GFP and firefly luciferase were used for control purposes.
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Tissue Harvesting
Mice were euthanized with an inhalation overdose of isoflurane (Vet One). Aortas were immediately flushed via the left ventricle with icecold PBS and then dissected from fat and connective tissue from the renal arteries to the diaphragm (via Microscope, Leica). Specimens were snap-frozen in liquid nitrogen and stored at −80°C.
Histological Staining
Histological staining after harvesting was performed in the correlating suprarenal region of the AAA. Using already evaluated techniques, 24 aortic tissue was cut in 7-µm-thick serial sections and subsequently stained with hematoxylin and eosin (Sigma-Aldrich) and Picrosirius red (Sigma-Aldrich) according to standard protocols. All histological analyses were obtained at room temperature using a Keyence BZ-9000 microscope with BZ2 Analyzer software. 
Flow Cytometry
Flow cytometry analysis for markers of T cell and macrophage polarization was performed in suprarenal aortic tissue at day 7 after Ang II infusion. Control mice were injected with saline instead of minicircle GFP to avoid interference with flow cytometry, whereas untreated animals received neither Ang II nor minicircle IL-10 treatment. Aortic tissue was digested with Liberase (27 WU/mL) and DNase I (0.1%) in DMEM media. Cells were counted and prepared for flow cytometry and 1×10 6 cells were used for staining. For intra-and extracellular staining, cells were fixed and permeabilized using BD Cytofix/ Cytoperm Fixation. Fluorophore-conjugated monoclonal antibodies against mouse CD3, CD4, CD8, CD25, CD45, FoxP3 (forkhead box P3), GZMB (granzyme B), F4/80, IL-10, MRC1 (mannose receptor, C type 1), TNF-α (tumor necrosis factor-α) and viability (1:100; BD Bioscience, Biolegend, eBioscience) were used. Cells were assayed using an LSRII flow cytometer (BD Biosciences) and further analyzed with FlowJo software (Tree Star, Ashland, OR).
Human Peripheral Blood Mononuclear Cell Experiments
Human peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy volunteers using a standard Ficoll protocol. Subsequently, cells were treated with Ang II (100 μmol/L) for 24 hours followed by lipopolysaccharide induction (100 ng/mL) for an additional 24 hours. IL-10 (20 ng/mL) or control treatment (PBS) was performed in combination with Ang II priming and before lipopolysaccharide stimulation. Cells were harvested using Qiazol and RNA was isolated using the Qiagen miRNeasy kit. RNA was quantified by Nanodrop (Thermo Fisher Scientific). mRNA was reverse transcribed using the SuperScript III RT kit (Thermo Fisher Scientific) according to the manufacturer's instructions and expression levels were quantified with standard quantitative real time-PCR (TaqMan) with the following assays: GAPDH (internal control), TNF, IL-6, TGFB1 (transforming growth factor beta-1), MRC1, CD163, FOXP3, GZMB, IL-10 (all Thermo Fisher Scientific). Amplification was performed using a Quantstudio 12K Flex Real-Time PCR system (Thermo Fisher Scientific). Results were normalized to GAPDH.
Statistical Analysis
All calculations were made with GraphPad Prism 6.01. Normal distribution was tested by Kolmogorov-Smirnov test and led to pairwise testing with Student unpaired t test. Otherwise, the Mann-Whitney rank-sum test was performed. For multiple comparisons, post hoc Fisher Least Significant Difference tests were calculated after 1-way repeated measures ANOVA. For curve comparisons of Kaplan-Meier survival curves, a Log-rank (Mantel-Cox) test was performed. For in vitro experiments, obvious outliers were removed using the Robust regression and Outlier removal method with a coefficient Q of 2%. 27 A P value of <0.05 was considered statistically significant. Data are presented as mean±SEM or median±interquartile range if data were not normally distributed or not interval scaled.
Results
To evaluate transfection efficacy of our intravenous minicircle injection approach, we first utilized minicircles expressing a firefly luciferase reporter construct (minicircle-Luc). Minicircle-Luc was injected and subsequent bioluminescence imaging was performed at days 1, 3, 9, and 15. We found a noticeable increase in luciferase activity in regions corresponding to the lungs at 1 to 3 days after transfection, with increasing activity in the liver and kidney regions over the course of the first 9 days ( Figure 1A) . By 15 days after transfection, the luciferase signal had significantly dropped, indicating a considerable loss of activity ( Figure 1B) .
Ang II treatment began at day 7 after minicircle transfection, to ensure active vector expression during aneurysm induction. We also evaluated IL-10 plasma levels of mice at 7 and 14 days after injection with minicircle IL-10 or minicircle control, confirming expression and production of IL-10 in a similar fashion to minicircle-Luc. We found a significant increase in plasma IL-10 levels in minicircle IL-10-treated mice (versus matched controls) at day 7 after transfection (161.3±14.6 versus 55.5±15.4 pg/mL; P<0.01; n=5; Figure 1C ). At day 14 after minicircle injection, no differences could be found for IL-10 expression in minicircle IL-10 versus minicircle control (46.8±13.4 versus 36.8±10.6 pg/mL; P=ns; n=4/5). To further evaluate the long-term effects of minicircle IL-10 injection on tissue levels of IL-10, expression in peripheral tissues were quantified with quantitative real time-PCR at day 28 after Ang II infusion. Here, IL-10 did not show significantly higher expression in aortic tissue, lung tissue, or hepatic tissue in comparison with minicircle control ( Figure 1D ). Interestingly, however, splenic IL-10 expression was significantly higher in minicircle IL-10 than in controls (2.52±0.5-fold increase versus minicircle control; P<0.01; n=10). This was accompanied by higher splenic Foxp3 expression at day 28 after Ang II (1.9±0.3-fold; P<0.05; n=10; Figure 1E ) but not increased TNF levels.
Subcutaneous Ang II pump implantation at day 7 after transfection led to significant suprarenal aortic aneurysm formation in ApoE −/− mice as previously described, 20 with 78% of the mice having a diameter of >150% of baseline in the control group. Aneurysm formation was attenuated in mice that had been injected with minicircle IL-10, as only 10% of these animals had a diameter increase of ≥150% (average diameter, 166.1±10.8% in control versus 131.0±5.8% in IL-10 treated animals; P<0.01; n=9 versus 10; Figure 2A ). Differences in diameter remained throughout the time course of aneurysm formation, starting at day 7 ( Figure 2A) . These findings were supported by H&E and Picrosirius Red stainings, which showed a relevant decrease in AAA diameter after minicircle IL-10 treatment ( Figure 2B ).
In the murine ApoE −/− Ang II infusion AAA model, aneurysm formation is typically driven by intramural hematoma or myointimal dissection of the aortic wall. Therefore, in addition to aneurysm size, the presence of a dissecting AAA is an important aspect of AAA formation. 28 In concert with the significantly decreased diameter after minicircle IL-10 treatment, we found improved dissecting AAA-free survival in animals transfected with the IL-10 vector (21.5% versus 62.3% at day 28 in Ang II versus Ang II minicircle-IL-10; P=0.01; n=41; Figure 2C ). Figure 4B ). Notably, the increased TNF-α/IL-10 ratio in Ang II-treated control animals was reversed with IL-10 transfection ( Figure 4C) Figure 4D ).
To further investigate translational potential in human cells, we primed human PBMCs with Ang II or Ang II/IL-10 before stimulation with lipopolysaccharides and evaluated expression of inflammatory markers. There was a significant reduction in inflammatory gene expression with Ang II/IL-10 versus Ang II alone for all markers except FOXP3 (0.07±0.01 Figure 5C ). Figure 6F ).
Discussion
Here, we show that systemic transfection with a nonimmunogenic delivery method using IL-10 expressing minicircles is feasible and effective in a murine model of AAA disease. Plasma IL-10 levels were significantly increased at 1 week after transfection in ApoE −/− mice, and IL-10 induction significantly decreased aneurysm size and likelihood of suprarenal dissecting AAA formation. These beneficial effects on aneurysm development were accompanied by a significant increase in T reg cells and a decrease in CTLs. Furthermore, local macrophages were more likely to differentiate into the alternatively activated M2-macrophages and express less TNF-α as well as more IL-10. Human PBMCs with IL-10 treatment after Ang II incubation showed ameliorated expression of differentiation markers GZMB, TNF-α, MRC1, CD163, and IL-6, indicating possible translational potential in the application of IL-10.
One major IL-10-induced antiinflammatory process in tissue is the induction of CD4 + CD25 + FOXP3 + T reg cells. 29 In general, their mechanism of action also involves production of IL-10 itself, 29, 30 providing a self-amplifying feedback loop, which we also identified. The induction of a subset of more antiinflammatory macrophages by T reg cells, 31 particularly the so-called deactivated M2c-macrophages which are thought to be important for tissue remodeling and matrix deposition, is also regulated by IL-10. 32, 33 In AAA disease, M2-macrophages are present in the later phases of development 34 and are involved in healing and prevention of further AAA growth. By contrast, activation and clonal expansion of CD8 + CTLs induces cell damage and apoptosis potentially worsening AAA disease, if not properly regulated. 35, 36 Because IL-10 has been shown to contribute to CD8 + CTL expansion under certain conditions, we monitored the CD8 + GZMB + CTL amount in tissue and calculated the ratio of T reg /CTL ratio to further characterize the impact of IL-10 on the T-cell population in the aortic wall. Using the Ang II-induced AAA model, we observed that systemic overexpression of IL-10 via single timepoint minicircle transfection led to aortic cell polarization into T reg cells and antiinflammatory M2-macrophages expressing MRC1. These changes in adaptive and innate immune cell differentiation were associated with a clear reduction in aneurysm formation. We did not find a significant change in CD3
+ or macrophage cell number in aortic tissue after minicircle injection. Therefore, our results suggest a polarization effect, rather than a recruitment. Considering the limited expression period of the minicircle-delivered plasmids of, at most, 2 weeks with regard to IL-10 plasma levels (when compared with the 4-week period of aneurysm development), it could be that this treatment might have sparked self-amplifying cascades and cell-cell interactions that maintain the antiinflammatory response. At 28 days after aneurysm induction, only splenic tissue showed increased expression of IL-10 ( Figure 1D ). This was accompanied by higher Foxp3 expression, possibly indicating pronounced T reg polarization ( Figure 1E ). This is especially intriguing because flow cytometry analysis of spleens at day 7 after Ang II showed significantly fewer CD4 + cells and a tendency toward fewer Foxp3-positive T reg cells ( Figure IVA and IVD in the onlineonly Data Supplement). This might indicate an initial mobilization of CD4 + cells from the spleen in response to Ang II, a redistribution process to nonlymphoid tissue known to occur after recognition of certain antigens. 37 Subsequently, splenic IL-10 and Foxp3 expression might increase again over the next 3 weeks if minicircle IL-10 expression had successfully induced antiinflammatory processes in the aorta.
In patients with AAA, both the number and function of T reg cells as well as the expression of FOXP3 are significantly decreased in peripheral blood, 38, 39 suggesting that the lack of T reg immunomodulation may accelerate AAA formation. Indeed, adoptive transfer of T reg cells to Ang II-treated ApoE −/− mice reduced AAA incidence and severity in a dose-dependent manner. 40 Furthermore, direct treatment with T reg cells decreased macrophage number and the expression of proinflammatory cytokines in local aortic tissue. After T reg treatment in vitro, macrophages had a more pronounced M2-like phenotype, consistent with previous reports. 31, 33 As such, the beneficial effects of T reg cells are likely mediated via direct cell-cell contact as well as paracrine effects.
Yodoi et al 41 demonstrated that the expansion of Foxp3 + T reg cells by IL-2 complex treatment resulted in a marked decrease in the incidence and mortality of AAA, and that this effect could be reversed by genetic depletion of Foxp3 + T reg cells, further underlining the importance of T reg cells in the prevention of aneurysm disease. Moreover, Zhou et al 39 further clarified the importance of IL-10 in mediating the beneficial effects of T reg cells in AAA formation. Transfusion of T reg cells from wild-type animals suppressed macrophage activation and reduced lesion macrophage and T-cell counts in the murine Ang II AAA model. However, this was not the case in mice that were infused with T reg cells from IL-10 −/− animals, suggesting that the presence of IL-10 is imperative for cellcell interaction of T reg cells with the surrounding tissue. IL-10 has also been shown to be a crucial regulator of inflammationmatrix interaction because T reg cells from IL-10 competent mice suppress MMP-9 (matrix metallopeptidase 9) and MMP-13 activity more strongly than T reg cells from IL-10 −/− mice. 39 Notably, IL-10 −/− mice show increased elastin degradation 11 and, T reg treatment inhibits apoptosis of aortic wall cells in the Ang II-induced aneurysm model. 40 Our data support a critical role for the mediator IL-10 in prevention of AAA formation and suggest that a transient increase in IL-10 might be sufficient to induce a critical mass of antiinflammatory T reg cells and regulatory macrophages at the site of lesion, thereby possibly decreasing AAA growth by positively modulating the inflammatory response, with potential downstream effects on extracellular matrix degradation and apoptosis via IL-10.
Recent work highlights the special considerations that need to be taken into account on the role of aortic dissection in the Ang II AAA model. 28, 42 Inflammatory cell infiltration tends to localize to sites of aortic dissection. 43 It is thought that classical activation of macrophages induces vascular dissection, thereby promoting AAA formation at least in part by an IL-6-dependent mechanism. 44 Our work suggests that readjusting the macrophage activation cascades using IL-10 treatment suppresses IL-6 as well as TNF-α expression and promotes MRC1 and CD163 transcription. The IL-10-induced increase in T reg cells and the shift from classical to alternatively activated macrophages in aortic tissue is therefore likely to be an important mechanism in the prevention of dissecting AAA. We assume that our antiinflammatory treatment primarily suppresses both micro-and macro-ruptures because these hemorrhagic events are thought to drive AAA growth in the Ang II-model. This is further underscored by the early separation of our AAA diameter and dissecting AAA-free survival curves (Figure 2A and 2B) at day 7 with a subsequently similar growth rate.
In PBMCs from healthy controls stimulated with Ang II, we observed minimal impact on inflammatory gene expression in the absence of IL-10 treatment. Our cells of interest, mainly monocytes/macrophages and T cells, all express receptors for Ang II 41, 45, 46 and should therefore be susceptible to Ang II priming. However, effects of Ang II on leukocytes seem to be context-sensitive 45, 47 and are difficult to duplicate in vitro. 48 We acknowledge that our understanding of Ang II-induced effects on mononuclear cells is not complete; nevertheless, IL-10 treatment was beneficial after PBMCs were primed with Ang II, supporting our main hypothesis that IL-10 initiates an antiinflammatory and self-amplifying polarization toward T reg cells and M2-macrophages.
There are limitations to our study. We applied the minicircle IL-10 vector systemically, once, and did not seek to control the site of expression nor the effect duration. It is possible that observed effects might be even stronger and display less off-target impact if a more specific approach to the vasculature or immune cells had been chosen. 49, 50 In addition, we cannot definitively conclude whether systemic or local increases of IL-10 are more important to prevent AAA formation because the cellular changes we induced in aortic tissue were observed after systemic IL-10 delivery with an initial increase of plasma IL-10. With regard to clinical applicability and the known methodological shortcomings of cell-specific transfections, we deliberately chose this approach, intending to maintain translational potential and seeking to prove that minicircles are feasible nonimmunogenic vectors for the treatment of AAAs in this mouse model. We did not seek to provide deeper mechanistic insights because the interaction of IL-10 with lymphocytes and myeloid cells has been extensively studied before. Although we do not provide hemodynamic data (such as blood pressure) in these animals, and therefore cannot exclude differences in minicircle-IL-10-treated versus non-minicircle-IL-10-treated animals, a recent publication suggests no prognostic value of hemodynamic markers on aneurysm growth. 51 Also, initial characterization of the model did not show any alteration in arterial blood pressure after Ang II infusion. 20 The recently published prevention of blood pressure increase by continuous IL-10 infusion has only been shown in combination with significantly higher doses of Ang II (90 ng/min) and vastly higher IL-10 levels (0.5 ng/min) when compared with our plasma IL-10 concentration. 52 In summary, we provide evidence that a one-time application of an IL-10 transcribing minicircle vector successfully limits aneurysm formation in a mouse model of AAA while increasing regulatory T cells and alternatively activated macrophages in the aortic wall. IL-10 treatment of PBMCs partially recapitulated the antiinflammatory effects of IL-10, indicating possible translational potential in humans.
